Navigation Links
Squire Sanders Stands Out in Independent Analysis of Law Firms in Europe
Date:4/17/2008

The Legal 500 EMEA 2008 Confirms Squire Sanders' Position as Market Leader

LONDON, April 17 /PRNewswire/ -- Global law firm Squire, Sanders & Dempsey L.L.P. has received a glowing review across a range of offices and practice areas in the highly respected independent legal guide The Legal 500 EMEA (Europe, Middle East and Africa) 2008. The publication employs a large team of journalists who conduct in-depth research, which forms a set of rankings and editorial analysis, reflecting the market as accurately as possible. The research includes interviews with peers (private practice lawyers and in-house counsel) as well as interviews with clients.

Squire Sanders is consistently recommended in banking & finance, M&A, dispute resolution, energy, real estate, competition and telecoms.

In Belgium, the firm was recommended in three EU regulatory categories (pharmaceuticals and bioscience, chemicals (REACH) and energy. The editorial commentary recognized the firm's "experience in clinical trials which is almost unparalleled."

The firm's team in the Czech Republic was acknowledged in six areas including "boasting a very strong disputes practice in the Czech Republic."

Squire Sanders' Hungary operation, which "advises on sizeable transactions, including instructions from Budapest Bank", was recommended in nine categories.

The team in Poland has "benefited significantly from its recent influx of lawyers from Baker & McKenzie," which brought with it strength in banking & finance, projects & energy, real estate and private equity.

In Russia, Squire Sanders has entered the real estate rankings following the hire of Dewey & LeBoeuf LLP real estate head Dmitry Kunitsa, who joined the firm with two associates. The move has "created a 'very strong practise' [according to one client] that spans finance, acquisitions and leasing."

The Slovak office has been commended for delivering "'immaculate' work for clients in Slovakia ...
'/>"/>

SOURCE Squire, Sanders & Dempsey L.L.P.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. NEWSWEEK: Media Lead Sheet/December 10, 2007 Issue (on newsstands Monday, December 3).
2. Biopure Appoints New Independent Auditor
3. Tianyin Pharmaceutical Appoints Three New Independent Board Members
4. New Independent Research Study Indicates That Cylexs ImmuKnow Test May Identify Kidney Transplant Patients at Risk for Early Acute Rejection
5. China Technology Appoints Deloitte Touche Tohmatsu CPA as Independent Auditor
6. China Pharma Appoints Three Independent Non-Executive Directors
7. Amarin Appoints Dr. William Mason as Lead Independent Director
8. Kiwa Fertilizers Pass Independent Tests
9. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R)
10. Roche to Nominate Independent Directors for Election at Ventanas 2008 Annual Stockholders Meeting
11. Mindray Announces Appointment of Dr. Jixun Lin as Independent Director
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:BioLife Solutions Announces Custom cGMP Manufacturing & License Agreement 2BioLife Solutions Announces Custom cGMP Manufacturing & License Agreement 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 2BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 3BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 2Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 3Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 5